Navigation Links
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood

nt, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products

###

This content was distributed through Hugin - connecting communication professionals/with their target audience. Visit us at
'"/>





Page: 1 2 3 4

Related medicine technology :

1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:5/1/2015)... , May 1, 2015  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic ... debridement, cosmetic surgery, laparoscopic surgery and other surgical ... results for the third quarter fiscal year 2015 ... scheduled a conference call that same day, Thursday, ...
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
(Date:4/30/2015)... 2015 Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its first quarter ... for the first quarter of 2015 was $116.2 million, ... of 2014, and down $5.3 million or 4.4% from ... 2015 net income as reported in accordance with U.S. ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27
... Mont., Feb. 1, 2012 Bacterin International Holdings ... leader in the development of revolutionary bone graft material ... Hayden IR , a 15-year-old, highly recognized, national investor ... relations program and raise its visibility and strengthen its ...
... 1, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Food and Drug Administration (FDA) has notified Arena that ... discuss the lorcaserin New Drug Application (NDA) resubmission will ... and details of the meeting will be published in ...
Cached Medicine Technology:Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 2Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 3Bacterin Retains Hayden IR to Develop Strategic Investor Relations Program 4Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 2Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 3Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin 4
(Date:5/2/2015)... FL (PRWEB) May 02, 2015 We ... selected The Delray Recovery Center as one of the ... is known in the addiction treatment field for their ... members to innovate and to continue their educational efforts. ... positive workplace environment, never forgetting their purpose – to ...
(Date:5/2/2015)... On Tuesday April 7th, the patient care ... celebrate improvements in patient care. In 2014 the hospital, ... zero acquired ventilator associated infections, zero central line associated ... also recently named a Top Performer by the Joint ... the teamwork of staff from all departments involved in ...
(Date:5/2/2015)... As a nonsurgical staple in ... face, neck and décolleté, radiofrequency energy is proving ... for the success of vulvovaginal rejuvenation. In a ... Council, ThermiGyn’s Women’s Health Clinical Advisory Board Chairman ... ThermiGyn’s temperature controlled radio frequency, specifically that of ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has ... Neida Miranda and Alex Shields to the team. With Neida ... years of combined experience working with dentists to ensure their ... for 8 years. She was certified as dental assistant ... positive attitude and showing the importance of oral hygiene to ...
(Date:5/1/2015)... and Caicos Islands, BWI (PRWEB) May 02, 2015 ... new website! It is http://www.thevenetiangracebay.com , and ... and it incorporates the stunning white and attractive turquoise ... a study of Google, sixty seven percent of leisure ... The study showed that smartphones were used in the ...
Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... TeleHealth Services , the nation,s ... staff interactive education solutions, today announced they will be ... the annual Healthcare Information and Management Systems Society (HIMSS) ... on-demand patient and staff education system, has been installed ...
... today announced the introduction of DNA shearing service ... years, Covaris instruments have become the gold standard ... step for next generation sequencing. The Covaris ... sequencing platforms. This process is highly reproducible ...
... Standards within HIT Solutions to Help Improve Patient ... Greenway Medical Technologies Inc., a leading ... practice management and interoperability solution has announced its ... Society (HIMSS) and Integrating the Health Enterprise (IHE) ...
... Ind., April 2 Despite government efforts to address ... 1998 Racial and Ethnic Health Disparities Initiative, there has ... and early death than Caucasians(1).The statistics are alarming:, ... African-Americans are 1.6 times more likely to have ...
... bouts of excessive consumption, CDC notes , , THURSDAY, April 2 ... most common among whites, males, people ages 18 to 34, ... to a study released Thursday. , The study defined binge ... , The U.S. Centers for Disease Control and Prevention (CDC) ...
... Discovery could lead to ways of regrowing damaged cardiac tissue, ... a longstanding mystery, scientists have found that the human heart ... although the rate of new cell production slows with age. ... of Science , could open a new path for ...
Cached Medicine News:Health News:TeleHealth Services Announces TIGR On-Demand Video Patient Education Version 7 Unveiling at HIMSS 2009 2Health News:TeleHealth Services Announces TIGR On-Demand Video Patient Education Version 7 Unveiling at HIMSS 2009 3Health News:Covaris Introduces DNA Shearing Service 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 3Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 4Health News:Health Disparities Among Minority Populations Getting Worse 2Health News:Health Disparities Among Minority Populations Getting Worse 3Health News:Typical Binge Drinker Is Young White Male 2Health News:Human Heart Can Make New Cells 2Health News:Human Heart Can Make New Cells 3
... cardiovascular system PLUS ... high-performance transesophageal cardiovascular imaging system ... phased array echocardiography system that ... images, even on your most ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
MAGNETOM Avanto, the worlds first Tim MRI system, provides unsurpassed image quality, enhanced productivity, and greater patient comfort....
... Medical Billing Assistant (MBA) ... medical billing and practice management ... on Microsoft SQL Server technology ... reporting capabilities and account receivable ...
Medicine Products: